MA46523A - Procédés de criblage de modulateurs d'une activité biologique de type gdf15 - Google Patents
Procédés de criblage de modulateurs d'une activité biologique de type gdf15Info
- Publication number
- MA46523A MA46523A MA046523A MA46523A MA46523A MA 46523 A MA46523 A MA 46523A MA 046523 A MA046523 A MA 046523A MA 46523 A MA46523 A MA 46523A MA 46523 A MA46523 A MA 46523A
- Authority
- MA
- Morocco
- Prior art keywords
- gdf15
- processes
- biological activity
- type biological
- screening modulators
- Prior art date
Links
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 title 1
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 title 1
- 230000004071 biological effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000012216 screening Methods 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Obesity (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662407046P | 2016-10-12 | 2016-10-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46523A true MA46523A (fr) | 2019-08-21 |
Family
ID=60186389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046523A MA46523A (fr) | 2016-10-12 | 2017-10-11 | Procédés de criblage de modulateurs d'une activité biologique de type gdf15 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20190234935A1 (fr) |
| EP (1) | EP3526346A1 (fr) |
| JP (1) | JP2020503842A (fr) |
| KR (1) | KR20190059312A (fr) |
| AU (1) | AU2017342028A1 (fr) |
| CA (1) | CA3038846A1 (fr) |
| IL (1) | IL265808A (fr) |
| MA (1) | MA46523A (fr) |
| WO (1) | WO2018071493A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY194669A (en) | 2016-03-31 | 2022-12-12 | Ngm Biopharmaceuticals Inc | Binding Proteins and Methods of use Thereof |
| US10336812B2 (en) * | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| EP3833974A2 (fr) | 2018-08-10 | 2021-06-16 | Novartis AG | Domaines extracellulaires gfral et procédés d'utilisation |
| EA202191105A1 (ru) | 2018-10-22 | 2021-08-03 | Янссен Фармацевтика Нв | Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение |
| KR20220150270A (ko) | 2019-10-07 | 2022-11-10 | 칼리오페, 인크. | Gpr119 효능제 |
| TW202140440A (zh) | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
| WO2021236617A1 (fr) | 2020-05-19 | 2021-11-25 | Kallyope, Inc. | Activateurs d'ampk |
| CN116390925A (zh) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | Ampk活化剂 |
| WO2023154953A1 (fr) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Polypeptides gdf15 pour le traitement et la prévention de maladies auto-immunes |
| JP2026505740A (ja) * | 2023-01-20 | 2026-02-18 | コリア アドバンスト インスティチュート オブ サイエンス アンド テクノロジー | Gfralを標的にするアンチセンスオリゴマー及びこの用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| US5770358A (en) | 1991-09-18 | 1998-06-23 | Affymax Technologies N.V. | Tagged synthetic oligomer libraries |
| KR100310939B1 (ko) | 1992-10-01 | 2002-06-20 | 추후제출 | 태그로암호화한복합조합화학라이브러리 |
| BR9407947A (pt) | 1993-11-02 | 1996-11-26 | Affymax Tech Nv | Processo para sintetizar moléculas diversas em uma pluralidade de substratos e uma coleçao molecular etiquetade para realizaçao reaçoes de copulaçao em contas em paralelo para triar uma coleçao molecular etiquetada para detectar a presença de um ou mais diferentes etiquetas e para determinar a sequência de síntese aparelho para reaçoes de copulaçao paralelas em suportes sólidos bloco de alinhamento ótico para uso com um detector ótico sistemas de distribuiçao para distribuir reagentes dispositiv |
| CA2189634A1 (fr) | 1994-05-06 | 1995-11-16 | John J. Baldwin | Bibliotheque combinatoire de dihydrobenzopyranes |
| US5663046A (en) | 1994-06-22 | 1997-09-02 | Pharmacopeia, Inc. | Synthesis of combinatorial libraries |
| US6010861A (en) | 1994-08-03 | 2000-01-04 | Dgi Biotechnologies, Llc | Target specific screens and their use for discovering small organic molecular pharmacophores |
| EP2441466B1 (fr) * | 2004-04-13 | 2014-07-23 | St Vincent's Hospital Sydney Limited | Agent inhibiteur de MIC-1 |
| EP2694092B1 (fr) * | 2011-04-08 | 2017-01-04 | Amgen Inc. | Méthode de traitement ou d'amélioration de troubles métaboliques à l'aide du facteur 15 de différenciation de croissance (gdf-15) |
| EP3683228A3 (fr) * | 2012-01-26 | 2020-07-29 | Amgen Inc. | Polypeptides du facteur de croissance et de différenciation 15 (gdf-15) |
| RS59700B1 (sr) * | 2014-03-26 | 2020-01-31 | Univ Wuerzburg J Maximilians | Monoklonalna antitela za faktor 15 (gdf-15) rasta i diferencijacije, i njihove upotrebe u lečenju kancerske kaheksije i kancera |
| JP6910800B2 (ja) * | 2014-06-20 | 2021-07-28 | アベオ ファーマシューティカルズ, インコーポレイテッド | Gdf15調節剤を用いたうっ血性心不全及びその他の心機能不全の治療 |
| PL3197493T3 (pl) * | 2014-09-25 | 2021-08-23 | Aveo Pharmaceuticals Inc. | Sposoby odwracania kacheksji i przedłużania przeżycia obejmujące podanie modulatora gdf15 i środka przeciwnowotworowego |
| CN108697795A (zh) * | 2016-02-29 | 2018-10-23 | 伊莱利利公司 | Gfral受体疗法 |
| MY194669A (en) * | 2016-03-31 | 2022-12-12 | Ngm Biopharmaceuticals Inc | Binding Proteins and Methods of use Thereof |
-
2017
- 2017-10-11 KR KR1020197012471A patent/KR20190059312A/ko not_active Withdrawn
- 2017-10-11 WO PCT/US2017/056069 patent/WO2018071493A1/fr not_active Ceased
- 2017-10-11 MA MA046523A patent/MA46523A/fr unknown
- 2017-10-11 AU AU2017342028A patent/AU2017342028A1/en not_active Abandoned
- 2017-10-11 EP EP17791242.5A patent/EP3526346A1/fr not_active Withdrawn
- 2017-10-11 US US16/341,074 patent/US20190234935A1/en not_active Abandoned
- 2017-10-11 CA CA3038846A patent/CA3038846A1/fr not_active Abandoned
- 2017-10-11 JP JP2019519691A patent/JP2020503842A/ja active Pending
-
2019
- 2019-04-03 IL IL265808A patent/IL265808A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20190234935A1 (en) | 2019-08-01 |
| WO2018071493A1 (fr) | 2018-04-19 |
| IL265808A (en) | 2019-06-30 |
| KR20190059312A (ko) | 2019-05-30 |
| CA3038846A1 (fr) | 2018-04-19 |
| EP3526346A1 (fr) | 2019-08-21 |
| AU2017342028A1 (en) | 2019-04-11 |
| JP2020503842A (ja) | 2020-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46523A (fr) | Procédés de criblage de modulateurs d'une activité biologique de type gdf15 | |
| FR24C1022I1 (fr) | Modulation d'activité du complément | |
| MA56008A (fr) | Composés et compositions pour traiter des états associés à une activité de nlrp | |
| MA46278A (fr) | Molécules de liaison qui modulent une activité biologique exprimée par une cellule | |
| MA50636A (fr) | Compositions et procédés pour inhiber l'activité d'arginase | |
| EP3383168A4 (fr) | Procédés de modification génétique de plantes | |
| EP3250230A4 (fr) | Modulateurs d'activité du complément | |
| EP3409108A4 (fr) | Couvre-lit pour lit d'animaux de compagnie | |
| EP3313385A4 (fr) | Agents d'alkylation d'adn contenant de l'aziridine | |
| EP3356832A4 (fr) | Biomarqueurs et procédés d'évaluation de l'activité de la maladie arthrite psoriasique | |
| EP3852617A4 (fr) | Procédés de réversion d'activité de ticagrélor | |
| EP3398776A4 (fr) | Composant de buse d'imprimante biologique et imprimante biologique | |
| EP3638283C0 (fr) | Antagonistes de canaux calciques de type cav2.3 r pour le traitement de maladies neurodégénératives | |
| EP3356523A4 (fr) | Machines d'état biologique | |
| EP3898438A4 (fr) | Bouteille à auto-agitation | |
| EP3261631A4 (fr) | Inhibition de l'activité d'olig2 | |
| EP3471534A4 (fr) | Végétaux à activité de la lipase 1 réduite | |
| IL282700A (en) | Heterocyclic compounds for the treatment of epilepsy | |
| MA41198A (fr) | Essais d'activité enzymatique pour i2s | |
| EP3480598A4 (fr) | Procédé de criblage d'anticorps à l'aide de cellules dérivées de patients | |
| EP3356515A4 (fr) | Test d'activité biologique cellulaire | |
| EP3603610A4 (fr) | Inhibiteur de l'activité de trpa1 | |
| EP3597040A4 (fr) | Agent de lutte contre les maladies des plantes | |
| EP3506748A4 (fr) | Procédés améliorés pour la synthèse de perméthrine | |
| EP3504195A4 (fr) | Inhibition de l'activité d'olig2 |